Physician profile
Scott D Ruffo
NPI 1972611531
$10,865.71
in general payments reported to CMS, 2019-2025
26 companies · $2,009 in 2025
The $2,009 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $240 · 2021: $2,483 · 2022: $980 · 2023: $3,370 · 2024: $1,336 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,694 · Travel and Lodging: $2,002 · Consulting Fee: $15.00 · Education: $5.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,693.75 |
| Travel and Lodging | $2,001.52 |
| Consulting Fee | $15.00 |
| Education | $5.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,131.24 | 2019-2025 | Aveir, Tendril, Gallant |
| Janssen Pharmaceuticals, INC | $716.16 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $325.49 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.42 | 2020-2025 | Lifevest |
| Recor Medical INC | $192.32 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cvrx, INC. | $184.55 | 2023-2025 | Barostim Neo System |
| Abiomed | $170.03 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $141.23 | 2022-2024 | Verquvo |
| Penumbra, INC. | $113.40 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.30 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $83.02 | 2019-2024 | Farxiga |
| Amgen INC. | $52.12 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $43.74 | 2020-2023 | |
| Novo Nordisk INC | $32.82 | 2023 | Wegovy |
| Preventice Services, LLC | $31.33 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.49 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $26.60 | 2023 | |
| Terumo Medical Corporation | $25.90 | 2025 | Metacross Otw |
| Impulse Dynamics (USA) INC. | $24.68 | 2024 | Optimizer |
| Kestra Medical Technology Services, INC. | $21.63 | 2025 | Assure Wcd |
| Infobionic, INC | $21.40 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $19.62 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 | |
| Esperion Therapeutics, INC. | $14.72 | 2023 | Nexletol |
| Portola Pharmaceuticals, LLC | $13.92 | 2019 | |
| Cashflow Solutions, LLC | $12.41 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ruffo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.